Loading
Revilico
We are on the forefront of pharmaceutical innovation levaraging machine learning, computational and synthetic biology, and a comprehensive understanding of disease modeling for optimized therapeutic approaches. Our team consists of high achieving scientists and engineers, pushing what is possible for pharmaceutical development and commercialization. We specialize in small molecule and protein therapeutics for revitalized therapeutics within the cancer domain. Our team utilizes a multifaceted approach to drug development and commercialization - including computational models in the realms of generative chemistry and protein dynamics, deep learning algorithms, financial engineering, data analytics, and physics-based mathematical modeling.
Funding
Every round, secondary, debt facility or acquisition involving Revilico that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
—